Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008 Jul;22(7):1472-4.
doi: 10.1038/leu.2008.6. Epub 2008 Jan 31.

Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation

R Jamal, C Bélisle, M-C Lessard, J Hébert, D-C Roy, R Levine, L Busque
Case Reports

Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation

R Jamal et al. Leukemia. 2008 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Temporal evolution between donor chimerism and appearance of the JAK2-V617F mutation after allogeneic stem cell transplantation. A: Chronic graft-versus-host disease, B: phenotypically normal host hematopoiesis, C: time to transformation and relapse into JAK2-V617F positive AML, D: progressive thrombocytosis and leucocytosis, E: start of Hydrea, F: AML relapse with 58% positivity for JAK2 in peripheral blood. AML, acute myeloid leukemia.
Figure 2
Figure 2
Sequence of events leading to both JAK2-V617F positive myeloproliferative disease (MPD) and its transformation into JAK2-V617F positive acute myeloid leukemia (AML) in a patient initially diagnosed with a JAK2-V617F-negative AML who underwent allogeneic stem cell transplantation. Shown in dashed lines: Potential pathway for transformation into JAK2-V617F-negative AML.
See this image and copyright information in PMC

References

    1. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107:2206–2211. - PubMed
    1. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108:346–352. - PubMed
    1. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377–1380. - PubMed
    1. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32–38. - PubMed
    1. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006;108:3548–3555. - PubMed